🔗 Share this article

An underground market for unapproved slimming medications is being driven by social media fitness personalities and sellers on communication apps, based on new investigations.

Experimental Treatment Gaining Traction Via Social Media

The experimental drug, which is still in research studies, is being promoted by social media influencers for its alleged fat-burning effects. Viewers are encouraged to contact these accounts directly for source information, while also obtaining promotional offers.

Active Trade on Social Networks

Separately, a robust market exists on messaging services, where communities with thousands of members share “before and after” images, injection guides and assertions of next-day British shipping. Vendors promote the substance there before redirecting buyers to other platforms for transactions.

Learning About The Experimental Drug

This medication is an investigational injection developed by US drugmaker Eli Lilly. The drug targets three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Early trials suggest it could assist individuals lose up to 25% of their total weight. Referred to as the “triple G”, the substance is being hailed digitally as the successor to Ozempic.

Medical Professionals Express Concerns

However, physicians and chemists have cautions that the distribution of what is still an unlicensed drug in the UK is worrisome and could lead to users injecting products of unknown origin.

Some experts said the demand for retatrutide could be connected to the increasing price of licensed weight loss treatments such as Mounjaro.

Legal Status and Implementation

Selling the unapproved drug on TikTok or messaging apps is illegal in the UK, as it is an unapproved drug that cannot be promoted or distributed for personal consumption under the Human Medicines Regulations 2012.

Some content creators attempt to circumvent the rules by referring to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted drug, but promotion and distribution can still breach medicines, advertising, and customer regulations, risking penalties, prosecution or prison.

Service Response and Material Elimination

Based on the social media company, the service has removed problematic material and prohibited associated keywords and search suggestions. The organization said it was dedicated to keeping the service safe and investing in enhancing compliance measures.

Online Marketplace Activities

Research also discovered groups with up to 9,000 members selling retatrutide using the platform's integrated discovery tool, which functions like a online catalog. Entering “retatrutide” instantly displays channels with numerous of users, populated with photos of weight loss, positive testimonials and step-by-step instructions for mixing or injecting at home.

After moments of entering one community, a vendor posted WhatsApp details, where the majority of transactions occur. The vendor provided an guidebook and promised delivery within two days. When asked whether the substance was authentic, one seller said: “You can’t be sure.” Another provided a photo of a supposed testing documentation. Not one asked about body mass, health issues or past usage.

Item Details and Pricing

Inside these groups, messages show black plastic packages with postal service labels, stating to contain new batches. One communication read: “It took eight of us to load them this morning.”

Buyers can choose between powder vials, mixed at home with sterile water, or pre-filled pens usually priced at 160 pounds for 20mg. When asked how much time a pen should be used, sellers give contradictory answers varying between a several days to “depends on your body”.

Platform Moderation and Security Measures

A representative for Telegram stated it actively monitored harmful material on its platform including material that promoted the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.

Medical Expert Cautions

“Individuals are administering substances they cannot confirm. Although the research behind this drug is sound, these online products may not include what they advertise,” stated a pharmacy expert, the director of pharmacy at a pharmacy service.

Dr Crystal Wyllie of an online medical service linked the surge in interest to recent cost increases for authorized weight-loss drugs such as Mounjaro. “With prices increasing, individuals are turning to social media. But counterfeit injections are highly dangerous. You can’t be certain what’s inside or whether the conditions they were produced in was sterile,” she explained.

Her team has previously encountered patients injured by self-injection from unverified suppliers. “We recognize the frustration, but buying from messaging apps or communication platforms is gambling with your health,” said Wyllie. “These materials could be contaminated or incorrectly dosed.”

Producer Statement

A representative from Eli Lilly stated retatrutide was in third stage clinical trials and had not been reviewed or approved by any government authority globally. “Consequently at this point no one can market [it] for human use,” they said, noting that any product “falsely representing itself as a company experimental product not yet authorized … may subject users to possibly significant health risks”.